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Nonalcoholic fatty liver disease (NAFLD) has emerged as a serious obesity-related
disorder, and it will continue to be a major liver health issue worldwide in the coming
decades. We aimed to determine the effect of Liv-Pro-08 (Nigella sativa, Entada
pursaetha, and Ficus glomerata) an oral ayurvedic formulation on rats fed with high-
fat diet. Rats were given a high-fat diet for a period of 7 days. After this period, Liv-
Pro-08 (250, 500, and 750 mg/kg.body weight was given orally for 7 days. We examined
the effect of the high-fat diet on various parameters related to obesity and insulin resis-
tance. In the experimental rats who received the extract of Liv-Pro-08, their lipoprotein
profiles were significantly improved compared with those that are not receiving the
extract. Also, a slight reduction was observed in serum aspartate aminotransferase,
alanine aminotransferase, and alkaline phosphatase enzymes. Moreover, Liv-Pro-08
significantly decreased their fasting serum glucose and fasting insulin levels. This exper-
imental study suggests that Liv-Pro-08 can act as a therapeutic tool in preventing NAFLD
progression (i.e., reducing hepatic lipid accumulation). Although further investigations
and large randomized trials should be conducted, ayurvedic Liv-Pro-08 oral formulation
may be a potential natural drug for NAFLD in the future.1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is becoming
a major public health problem due to the increasing inci-
dence of diabetes, obesity, and insulin resistance in India
for the last two decades [1,2]. NAFLD comprises a wide
spectrum of liver diseases that develop in the absence of
significant alcohol consumption (b20 g ethanol/day) orof Biochemistry, Periyar Univers
hey have received a Rajiv Gandhi
uncture Instituteother known causes of steatosis (e.g., abuse of drugs or
toxins). The earliest and most common type of this liver
disease is simple steatosis, which has long been thought to
be a relatively benign state of liver injury. However, results
from human studies indicate that fatty livers are more
vulnerable to injury from various causes [3], and they can
progress to steatohepatitis, thereby increasing the proba-
bility of further liver-related morbidity and mortality [4].ity, Salem-11, TN, India.
National Fellowship.
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liver. It progresses to increased mobilization of the fatty
acids from peripheral adipose depots; decreased utilization
of fatty acids by the liver; increased hepatic fatty acid
synthesis; decreased secretion of fat from the liver; and
increased esterification of fatty acids into triglycerides
[5,6]. This condition may lead to net fat accumulation in
hepatocytes.
NAFLD affects approximately 15%e40% of people living
in Western countries and 9%e40% of those in Asian coun-
tries. Urbanization and associated lifestyle changes, such as
sedentary lifestyle and a fat-rich diet, adversely affect the
risk factors of diabetes, unmasking the high genetic
tendency that already exists in the Indian population. It has
also been shown that Asian Indians have a higher body fat
percentage and an adverse body fat pattern, including
abdominal adiposity even when the body mass index is
within currently defined normal limits [7]. Attempts to
control its ill effect with lifestyle measures, physical
activity, and antiobesity drugs are currently in vogue.
However, herbal medicines have been used to treat liver
diseases for a long time. A number of herbal preparations
are available on the market, but there is scarce information
about the effect of medicinal plants on NAFLD.
Herbal medicines are considered “nature’s pharmacy”
and form a major component in all indigenous traditional
medicines [8]. It is a common element in Ayurveda,
homoeopathy, naturopathy, Unani, traditional oriental, and
Native American Indian medicines [8]. The sophistication of
herbal remedies used around the world varies with the
technologic advancement of the countries that produce and
use them [8]. The plants used for the present study were
Nigella sativa, Entada pursaetha, and Ficus glomerata (Liv-
Pro-08). We studied the possible protective role of Liv-Pro-
08 with NAFLD rats that were fed a diet high in fat.
Nigella sativa, which is one of species of the Ranuncu-
laceae family, is a seed that is frequently added to bread
and pickles as a flavoring agent. The seeds have been used
as a natural remedy for many ailments over many centuries
[9,10]. E pursaetha belongs to Mimosaecea family. The
Entada species have two amorphous saponins. The seeds
have various medicinal uses, e.g., as a topical application in
an ointment for the treatment of jaundice [11]. Ficus
glomerata (family: Moraceae) is more commonly known as
an atthi in Tamil and a cluster fig in English. The fruits are
effective against leprosy, diseases of the blood, fatigue,
bleeding nose, cough, diabetes, and leucoderma [12]. Both
the root and the bark are credited with hypoglycemic
activity [13]. N sativa, E pursaetha, and the dry fruit Ficus
glomerata have been part of a high nutritional diet in many
parts of the world, especially N sativa [14] and F glomerata,
which are used as spices in cooking and as a carminative
and diuretic by Asians all over the world.2. Materials and methods2.1. Sample collection
The seeds (N sativa and E pursaetha) and dry fruit
(F glomerata) were collected fromKolli Hills in the NamakkalDistrict, Tamilnadu, India. Historically, plants have been
used as a folkmedicine against various types of diseases [15].
2.2. Preparing the extract
The seeds and the fruit were washed, shade dried, and then
made into fine powder; 1 g of the fine ground sample was
weighed into a test tube, 10 ml ethanol was added, and the
sample was then extracted for 2 hours in a water bath at
65 C. After extraction, the sample was cooled to room
temperature and then centrifuged at 1500 rpm for 15 min.
The sample residue was extracted repeatedly with 30 ml of
ethanol. The extract was filtered with filter paper and
evaporated to remove the ethanol. Then, the concentrated
extract was stored at 4 C until use.
2.3. Animals and experimental protocols
Five male albino rats of the Wistar strain that weighed
200e230 g were obtained from animal stock in the Institute
of Veterinary Preventive Medicine (IVPM), Ranipet, Tamil-
nadu. The animals were housed in a well-ventilated
experimental animal house under constant environmental
and adequate nutritional conditions throughout the period
of the experiment. Feeding of animals was done ad libitum,
along with drinking water. All experiments on the rats were
carried out in absolute compliance, which also considers
the ethical guide for the care and use of laboratory
animals. Rats were given a normal diet for 1 week in order
to adapt to the vivarium conditions, and then they were
randomly divided into five groups (nZ 1 per group). The
five groups consisted of the normal controls, those fed
a high-fat diet, and those fed a high-fat diet with water-
soluble fraction of the ethanol extract of Liv-Pro-08 in
various concentrations (250, 500, and 750 mg/kg.b.wt). The
hepatic steatosis model was induced by a high-fat diet. Rats
were given the high-fat diet (coconut oil, 1 ml; egg yolk,
1 g; ghee, 1 g, and vanaspathi,1 g) by mouth every day for 1
week, with the exception of the control group that received
equal volume of saline alone. In the treatment groups, 250,
500, and 750 mg/kg.b.wt of Liv-Pro-08 were given orally
over a period of 7 days in rats given the high-fat diet. After
7 days the rats were sacrificed and blood samples were
collected for biochemical analysis.
2.4. Biochemical analysis
The serum level of the lipoprotein profiles ([total cholesterol
(CHOD/PAPmethod)], triglycerides (GPO/PAPmethod), Span
diagnostics ltd, G.I.D.C. Sachin 394230, SURAT, GUJARAT),
high-density lipoprotein [(HDL), polyethylene glycol precipi-
tation method) and low-density lipoprotein (LDL) were
determined by using enzymatic kits. Alkaline phosphatase
(ALP), aspartate aminotransferase (AST), and alanine
aminotransferase (ALT) were assessed by kit method (ready-
made reagent, it includes all the compositions) [16,17].
2.5. Insulin resistance status
Serum insulin was assayed using the kit method. The
physiologic index of insulin resistance was the homeostatic
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was assessed from fasting glucose and fasting insulin
concentrations using the following formula: HOMA-IRZ
[fasting insulin x fasting glucose] / 22.5.
2.6. Statistical analysis
All values are expressed as mean standard deviation (SD).
The significance of the differences between the means of
the tests and of the controls were calculated by a one-way
analysis of variance, and p values less than 0.05 were
considered significant.
3. Results
Ayurveda is a type of traditional medicine that deals not
only with the treatment of some diseases, but it is
a complete way of life [18]. This Indian system of medicine
has laid down principles and methods of treatment for
various diseases, including chronic illnesses, where there is
no definite curative treatment [18]. Symptomatic relief is
the only existing treatment option. Our qualitative phyto-
chemical results showed the presence of alkaloids, phenols,
flavonoids, and steroids. The Liv-Pro-08 was found to be
safe up to 1000 mg/kg.b.wt with no sign of change in the
behavioral patterns of the rats, which suggests that the
plant extract is nontoxic and appears to be safe.
3.1. Effects of Liv-Pro-08 on insulin resistance
Fig. 1 represents the effects of Liv-Pro-08 at doses of 250,
500, and 750 mg/kg.b.wt, once a day for 7 days. It shows
that Liv-Pro-08 reduced NAFLD in a dose-related manner.
The oral administration of Liv-Pro-08 at 250, 500 and
750 mg/kg.b.wt decreased the progression of NAFLD. Rats
fed a high-fat diet for 2 weeks showed no difference in body
and liver weight in either of the groups.
The physiologic index of insulin resistance was assessed
from fasting glucose and fasting insulin concentration using
the HOMA-IR approach. Treatment with Liv-Pro-08 signifi-
cantly decreased fasting serum glucose in group III (250 mg/Figure 1 Effect of the Liv-Pro-08 on serum insulin resistance st
(HOMA) of insulin resistance index. Group I (control), group II (high
(high-fat dietþ 500 mg/kg.b.wt), and group V (high-fat dietþ 750
of triplicate measurements of each sample. *p< 0.05 compared wkg.b.wt), IV (500 mg/kg.b.wt) and V (750 mg/kg.b.wt)
(103.33 0.76, 107.16 1.04 and 109.13 1.04, respec-
tively) when compared with group II (119.80 0.51),
whereas group III was similar to group I (103.00 0.50).
Insulin levels and the HOMA index were higher in rats fed
a high-fat diet (12.80 0.10 and 68.15 0.78) than in
controls (12.10 0.36 and 55.36 1.75), and serum insulin
and HOMA level were decreased significantly in the treat-
ment groups who received 250, 500 and 750 mg/kg.b.wt
(12.20 0.20, 12.06 0.20, 12.10 0.36 and 56.02 1.19,
58.36 0.66, 58.70 2.04, respectively). This was similar
to that of the control group.
3.2. Effects of Liv-Pro-08 on the serum lipoprotein
profile
To analyze the possible role of Liv-Pro-08 in lipid metabo-
lism, which is the key factor in the formation of the fatty
liver, Triglycerides (TG), Total cholesterol (TC), HDL, and
LDL were investigated. The increased serum levels of TG,
TC, as well as the serum LDL level, were significantly sup-
pressed (Fig. 2), whereas the decreased serum HDL (high-
fat diet group: 28.50 0.30) level was obviously elevated
by the Liv-Pro-08 treatment in the rats fed the high-fat diet
compared with the control group (31.33 1.52). These
results suggest that the Liv-Pro-08 can prevent hep-
atosteatosis via the down regulation of lipid accumulation
in serum.
3.3. Effects of Liv-Pro-03 on the serum liver marker
enzymes
The level of liver marker enzymes is determined to assess
liver function. Serum liver marker enzymes (ALP, ALT, and
AST) in all treatment groups (250, 500 and 750 mg/kg.b.wt)
were lower than the group II relative to the control rats.
Treatment with Liv-Pro-08 in groups III, IV, and V had
significantly reduced serum levels of the aforementioned
enzymes (ALP, 113.50 0.50 to 117.86 1.10; ALT,
32.10 0.10 to 32.53 0.25; and AST, 22.13 2.20 to
25.83 0.60), whereas the 250 and 500 mg/kg.b.wt groupsatus. It is presented using the homeostatic model assessment
-fat diet), group III (high-fat dietþ 250 mg/kg.b.wt), group IV
mg/kg.b.wt of Liv-Pro-08). Results shown as mean SD (nZ 1)
ith high-fat diet. yp< 0.05 compared with control.
Figure 2 Effect of the Liv-Pro-08 on serum lipid profile.
Group I (control), group II (high-fat diet), group III (high-fat
dietþ 250 mg/kg.b.wt), group IV (high-fat dietþ 500 mg/
kg.b.wt), and group V (high-fat dietþ 750 mg/kg.b.wt of Liv-
Pro-08). Results shown as mean S D (nZ 1) of triplicate
measurements of each sample. HDLZ high density lipoprotein;
LDLZ low density lipoprotein; TCZ total cholesterol;
TGZ triglyceride. *p< 0.05 compared with a high-fat diet.
yp< 0.05 compared with controls.
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blood compared with the control group (Fig. 3). This result
implies that the Liv-Pro-08 has a protective effect against
high-fateinduced liver damage.4. Discussion
NAFLD is a common disease characterized by excessive
triglyceride accumulation in the liver. Nowadays, widelyFigure 3 Effect of the Liv-Pro-08 on serum hepatic enzymes.
Group I (control), group II (high-fat diet), group III (high-fat
dietþ 250 mg/kg.b.wt), group IV (high-fat dietþ 500 mg/
kg.b.wt), and group V (high-fat dietþ 750 mg/kg.b.wt of Liv-
Pro-08). Results shown as mean SD (nZ 1) of triplicate
measurements of each sample. ALPZ alkaline phosphatase;
ALTZ alanine aminotransferase; ASTZ aspartate amino-
transferase. *p< 0 .05 compared with a high-fat diet. yp< 0.05
compared with controls.grown herbs and herbal formulations have been found to
possess beneficial activities for treating hepatic disorders
[19]. As with most human diseases that driven by diet, the
fatty liver in rodents is also diet-inducible. A high-fat diet
increases liver fat levels quite rapidly, e.g., within days,
even before significant increases in peripheral fat deposi-
tion occur. High-fat diet could play a potential role in the
pathogenesis of NAFLD. Our study results demonstrated
that secondary metabolites, particularly alkaloids, flavo-
noids, phenols, and saponins from the Liv-Pro-08 possessed
a significant hepatoprotective effect based on the deter-
mination of lipid profiles and hepatic enzymes (Figs. 2 and
3), suggesting that these secondary metabolites may be
developed as a potential hepatoprotective drug. Phyto-
chemical investigations of the ethanolic extract of Liv-Pro-
08 possess secondary components, which may reduce
NAFLD.
A recent trial studied a choline deficient and a high-fat
diet to examine the effects of excess liver fat on the insulin
resistance and glucose tolerance that accompanies diet-
induced obesity [20]. The results suggested that the
administration of Liv-Pro-08 protected against the devel-
opment and progression of hepatic steatosis induced by
a high-fat diet. As a causative factor of NAFLD and sup-
ported by reductions in serum lipids (TC, TG and LDL), the
researchers observed Liv-Pro-08-administered in albino
rats. Free fatty acids are esterified into TG and then
exported as VLDL. Failure of synthesis and secretion of
VLDL can further contribute to TG accumulation in the liver
[21]. Al-Hader et al. reported that the N sativa seed
decoction reduced blood glucose within 1 month, as well as
plasma cholesterol and triglycerides thereafter. Indeed,
Wang et al. demonstrated protective effects against
hepatic steatosis in rats fed a high-fat diet. They showed
that the flavonoids of Litsea coreaneleve also improved the
release of adipocytokines and increased the expression of
the peroxisome proliferator activated receptor-a [22].
Dysregulation of triglycerides and free fatty acids, which
result in the accumulation of lipids in the liver and the
induction of oxidative and inflammatory stress, favor the
progression of NAFLD. They were markedly reduced in rats
in the high-fat diet group whose diet was also fortified with
the Liv-Pro-08. Hepatic lipid accumulation generally occurs
as a result of an increase in the supply of circulating free
fatty acids to the liver, but it can also result from increased
endogenous hepatic fatty acid synthesis [23]. Aqueous
extract of N sativa normalized body weight in the obese
diabetic models of Psammomys obesus [24] or Meriones
shawi [25] sand rats. A significant reduction in blood
glucose and cholesterol levels in humans was also reported
by Bamosa [26].
The rat model used in this study mimics the typical Indian
dietary habits which contains high-fat. The results confirm
that a high-fat diet increases the serum levels of triglycer-
ides, LDL cholesterol, as well as serum insulin, and results in
an impaired HOMA index. In the case of high dietary intake
of fats, animal studies have shown that fatty liver is the
result of increased delivery of fatty acids through the portal
circulation together with a 25% higher de novo lipogenesis
[27]. Petroleum ether extract of the stem bark of N sativa
plant reduced blood sugar level significantly [28], and this
study supported our present work as very effective and
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to be safe up to 2000 mg/kg with no sign of mortality or
change in behavior. These results suggests that the plant
extract is safe and nontoxic [29].
Increased concentrations of serum enzymes such as ALT,
AST, and ALP have been observed in diets high in fact, which
led to increased permeability, damage, steatosis, and
inflammation in our rats [30]. In our work, the results
demonstrated that phenols, flavonoids, and saponins from
the Liv-Pro-08 possessed a significant hepatoprotective
effect based on the determination of hepatic enzymes
(Fig. 3). This suggests that the various concentrations
of the Liv-Pro-08 treatment significantly reduced liver
marker enzymes concentration in high-fat dieteinduced
groups.
In previous papers, some of the results showed that the
lipid fraction of N sativa was rich in linoleic acid, which has
a beneficial effect on blood lipids, and serum cholesterol
[31]. Their unique fatty acid composition, relatively high
polyphenol content and quality, and, hence, a high
protection against oxidative stress, as well as a relatively
good shelf life and other desirable physiochemical charac-
teristics may lead to more diverse and novel applications of
the Ni sativa seed in food, pharmaceuticals, cosmetics, and
other nonfood industries [32].
E pursaetha can be used as a tonic for liver troubles,
allaying body pains and arthritis [33]. Khanal and colleagues
reported that saponins from the root of Platycodon gran-
diflorum supplementation may antagonize the develop-
ment of oxidative liver injury by depressing the elevation of
the CYP2E1 protein expression and through its ability to
scavenge free radicals [34]. E pursaetha also has a saponin
component that may avert the development of hepatic
steatosis.
These results indicate that the Liv-Pro-08 attenuates the
disorders of lipid metabolism in liver that resulted from
a high-fat diet. The inhibitory effect of the Liv-Pro-08 on
hepatic steatosis appeared to be related to the suppression
of lipogenesis enzyme activity and the acceleration of fatty
acid oxidation in the group that was fed a high-fat diet.5. Conclusion
Our results suggest that the Liv-Pro-08 reduces hepatic
steatosis and has lipid-lowering effects in Wister albino rats
fed a high-fat diet. These effects are apparently mediated
by the down regulation of lipid molecules involved in the
lipogenesis and modulation of the hepatic lipid metabolism-
related enzyme activity. These findings suggest that the
Liv-Pro-08, which contains secondary plant metabolites,
may be useful as a potential dietary intervention for those
with hepatic steatosis and hyperlipidemia.Acknowledgments
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